Company: SWKH
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050155
Chunk: 82

Company: SWK Holdings Corp
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 82
---
 reportable segments. The management approach is based on the way that management organizes the segments within the Company for making operating decisions, allocating resources, and assessing performance. Consequently, the segments are evident from the structure of the Company’s internal organization, focusing on financial information that the Company’s CEO uses to make decisions about the Company’s operating matters.As described in Note 1, SWK Holdings Corporation and Summary of Significant Accounting Policies, the Company has determined it has two reportable segments: Finance Receivables and Pharmaceutical Development, and each are individually managed and provide separate services. Revenues by segment represent revenues earned on the services offered within each segment. The Company does not report assets by reportable segment, nor does the Company report results by geographic region, as these metrics are not used by the Company’s chief executive officer in assessing performance or allocating resources to the segments.Segment performance is evaluated based on several factors, including income (loss) from continuing operations before income taxes. Management uses this measure of profit (loss) to evaluate segment performance because the Company believes this measure is indicative of performance trends and the overall earnings potential of each segment. The following tables present financial information for the Company's reportable segments for the periods indicated (in thousands):Three Months Ended September 30, 2025Finance ReceivablesPharmaceutical Development and OtherHolding Company and OtherConsolidatedRevenue$10,822 $— $— $10,822 Other revenue60 — — 60 Benefit from credit losses(931)— — (931)Loss on impairment of intangible assets— 209 — 209 Interest expense240 13 926 1,179 Pharmaceutical manufacturing, research and development expense— 147 — 147 Loss on disposal of inventory— 314 — 314 Depreciation and amortization expense— — 2 2 General and administrative expense110 258 2,918 3,286 Other income expense, net2,419 1,601 — 4,020 Income tax expense— — 1,916 1,916 Net income (loss)13,882 660 (5,762)8,780 Three Months Ended September 30, 2024Finance ReceivablesPharmaceutical Development and OtherHolding Company and OtherConsolidatedRevenue$9,498 $628 $— $10,126 Other revenue289 3 —